Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-M
about
An update of current treatments for adult acute myeloid leukemiaPreclinical examination of clofarabine in pediatric ependymoma: intratumoral concentrations insufficient to warrant further study.Low-dose clofarabine in combination with a standard remission induction in patients aged 18-60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: combined phase I/II results of theA phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia.
P2860
Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-M
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Clofarabine in combination wit ...... myelodysplastic syndrome (HR-M
@en
Clofarabine in combination with a standard remission induction regimen
@nl
type
label
Clofarabine in combination wit ...... myelodysplastic syndrome (HR-M
@en
Clofarabine in combination with a standard remission induction regimen
@nl
prefLabel
Clofarabine in combination wit ...... myelodysplastic syndrome (HR-M
@en
Clofarabine in combination with a standard remission induction regimen
@nl
P2093
P2860
P1433
P1476
Clofarabine in combination wit ...... TC GIMEMA 06061/AML-14A trial)
@en
P2093
C J M Halkes
M Karrasch
R Willemze
T de Witte
P2860
P304
P356
10.1007/S00277-014-2056-6
P577
2014-03-29T00:00:00Z